Clinical trialPhase 2Enrolling by invitation
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
A Phase II Study of Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel as a First-line Treatment for Subjects With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Enrolling by invitation
- Study type
- Interventional
- Start
- 1 July 2023
- Listed end
- September 2026
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- Progression-free survival time
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 13 July 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to determine the efficacy of sitagliptin combined with gemcitabine and albumin-bound paclitaxel in subjects with locally advanced and metastatic pancreatic ductal adenocarcinoma.
Detailed description public domain (ClinicalTrials.gov)
This is a single-institution, prospective, open, one-armed phase Ⅱ clinical trial of sitagliptin combined with gemcitabine and nab-paclitaxel.
Papers 1
- Registry-listed results paperSitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reduc… DOI 10.1038/s41392-026-02966-0↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.